Equities

Harvard Bioscience Inc

Harvard Bioscience Inc

Actions
  • Price (EUR)2.18
  • Today's Change0.10 / 4.81%
  • Shares traded--
  • 1 Year change-43.81%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 16:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4.284.517.82
Total Receivables, Net202026
Total Inventory252628
Prepaid expenses------
Other current assets, total------
Total current assets495162
Property, plant & equipment, net8.759.1810
Goodwill, net575658
Intangibles, net162127
Long term investments------
Note receivable - long term------
Other long term assets6.047.455.17
Total assets137145162
LIABILITIES
Accounts payable5.556.454.91
Accrued expenses9.388.6411
Notes payable/short-term debt000
Current portion long-term debt/capital leases5.863.813.24
Other current liabilities, total5.754.356.00
Total current liabilities272325
Total long term debt314345
Total debt374748
Deferred income tax0.780.591.56
Minority interest------
Other liabilities, total6.276.296.97
Total liabilities647379
SHAREHOLDERS EQUITY
Common stock0.430.450.45
Additional paid-in capital232229226
Retained earnings (accumulated deficit)(146)(142)(133)
Treasury stock - common----0
Unrealized gain (loss)------
Other equity, total(14)(15)(10)
Total equity737283
Total liabilities & shareholders' equity137145162
Total common shares outstanding434241
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.